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Testosterone Treatment in Older Men
To the Editor: In 1990, the Journal published 
the results of a study involving 12 men who were 
61 to 81 years of age and who had low levels of 
insulin-like growth factor 1. This study indicated 
that after 6 months of receiving injections of hu-
man growth hormone, the effects of 10 to 20 years 
of aging on lean muscle and fat mass were re-
versed.1 The article led to hyped claims of a foun-
tain of youth.2 The Journal then published two 
cautionary opinion pieces3,4 stating that the study 
was too short to reveal adverse effects and to serve 
as the basis for treatment recommendations.
Now, with the article on the Testosterone Trials 
by Snyder et al. (Feb. 18 issue),5 history repeats it-
self. These trials are also too small and too brief to 
detect dangerous adverse effects noted in the pack-
age labeling for testosterone. Furthermore, 63% of 
the participants in the present trials were obese. 
The majority of purported cases of “low T” are ac-
tually cases of what I have termed “pseudohypo-
gonadism,” in which obesity (which can cause low 
testosterone levels) is much more likely than low 
testosterone levels to cause poor sleep and de-
creased libido, as well as to decrease the ability to 
exercise.6 Good sleep hygiene, proper diet, and 
regular exercise are much safer and more effi-
cacious than potentially life-threatening testoster-
one supplementation.
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To the Editor: The trials by Snyder et al. provide 
important data on the benefits of testosterone-
replacement therapy with respect to sexual function 
in men with symptomatic hypogonadism. The use 
of phosphodiesterase type 5 inhibitors was per-
mitted during the trials; this was specifically stat-
ed in the protocol. Given the established benefits 
of phosphodiesterase type 5 inhibitors,1 it would 
be very interesting and clinically meaningful to 
know the sexual outcome in patients who received 
concomitant therapy with phosphodiesterase type 
5 inhibitors and in those who did not. Relevant 
analyses might be very helpful and might unveil 
any independent or additional effect of testoster-
one-replacement therapy on sexual function.
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The cardiovascular safety of testosterone-
replacement therapy remains controversial, and 
contradictory data have been reported in the litera-
ture.2,3 Although the follow-up was short and the 
trials by Snyder et al. were underpowered to assess 
cardiovascular safety, it would be important to 
know the effects of testosterone-replacement thera-
py on traditional cardiovascular risk factors (i.e., 
blood pressure, glucose and lipid levels, and body-
mass index).4 Moreover, it would be interesting to 
know whether the outcome was affected by the 
baseline characteristics of the patients (e.g., hyper-
tension, diabetes, dyslipidemia, and obesity).
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To the Editor: Snyder and colleagues targeted 
total testosterone levels within the “normal” range 
(280 to 873 ng per deciliter) for men who were 19 to 
40 years of age. Endocrine Society guidelines dic-
tate that hypogonadism should be diagnosed on 
the basis of a combination of a low serum testos-
terone level and a constellation of symptoms.1 The 
trials by Snyder et al. targeted a numerical end 
point rather than symptom relief. Post-treatment 
testosterone levels do not correlate linearly with 
symptoms2; thus, the dosage should be individu-
alized. Increasing strength and decreasing fatigue, 
for example, may require a higher testosterone level 
than that which is needed to increase libido.
Although the authors reported post-treatment 
median free testosterone levels of approximately 
150 pg per milliliter, examination of the inter-
quartile range reveals that approximately 25% of 
men had potentially subtherapeutic levels of free 
testosterone (<100 pg per milliliter); these sub-
therapeutic levels are lower than the threshold for 
men who reported symptoms in the European Male 
Aging Study.3 Furthermore, free testosterone lev-
els correlate poorly with hypogonadal symptoms.4
Their trials, although important, do not reflect 
contemporary practice, since they targeted a nu-
merical end point rather than symptoms. Trials 
that target symptoms and that would shed light on 
the benefits and risks of testosterone are lacking.
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To the Editor: In the trials by Snyder et al., men 
were selected for enrollment on the basis of total 
testosterone concentrations (<275 ng per deciliter) 
plus sexual symptoms, slow gait, or fatigue. We are 
concerned that most of these men probably did not 
have low free testosterone levels and did not meet 
current diagnostic criteria for male hypogonadism.
In the European Male Aging Study, late-onset 
hypogonadism was defined both by low total and 
free testosterone levels and by sexual symptoms.1 
Recently, we found that low free testosterone con-
centrations were associated with androgen defi-
ciency–related symptoms and signs, whereas this 
is not the case in men with normal free and low 
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total testosterone concentrations.2 Guidelines on 
the evaluation of male hypogonadism also sug-
gest measurement of free testosterone levels in 
men with total testosterone levels that are near 
the lower limit of the normal range or those 
with conditions such as obesity that might affect 
levels of sex hormone–binding globulin.3 There-
fore, we wonder why the free testosterone level 
was not considered as an inclusion criterion and 
whether the findings of the trials differed accord-
ing to baseline concentrations of free testosterone 
or sex hormone–binding globulin.
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The authors reply: Perls and Stavropoulos et al. 
comment that the Testosterone Trials were not de-
signed to determine the risk of testosterone treat-
ment. Our trials were designed to implement the 
recommendation of the Institute of Medicine that 
trials of efficacy were needed before it could be 
determined whether a trial of risk was justified.1
Perls also notes that many participants in our 
trials were obese. Because obesity is common in 
the United States, the results should be general-
izable to men 65 years of age or older who have 
a low testosterone level. In spite of obesity, the 
free testosterone level in participants was also 
low, and testosterone treatment resulted in both 
symptomatic and objective benefits.
Stavropoulos et al. also ask about the effect 
of phosphodiesterase type 5 inhibitors on the 
sexual-function results. Fewer than 10% of men 
in the trials received phosphodiesterase type 5 
inhibitors, and this rate was well-balanced be-
tween the two study groups, so we are not able 
to compare outcomes between the two groups.
Mata et al. suggest that targeting relief of 
symptoms would have been better than targeting 
a serum testosterone concentration. The goal of 
the Testosterone Trials was to determine wheth-
er increasing the serum testosterone concentra-
tion to within the normal range for young men 
would reduce both symptoms and objective defi-
ciencies. We did not want to increase the serum 
testosterone level above normal because of the 
concern that doing so would increase risk.
Laurent et al. propose that the level of low free 
testosterone, rather than the level of total testos-
terone, should have been the basis for inclusion 
in the Testosterone Trials. As shown in Figure S2 
in the Supplementary Appendix of our article 
(available with the full text of the article at NEJM 
.org), median serum free testosterone levels were 
less than half of the median of the normal level 
at baseline and they more than doubled during 
treatment; this is similar to the pattern for total 
testosterone.
Peter J. Snyder, M.D. 
Susan S. Ellenberg, Ph.D. 
John T. Farrar, M.D., Ph.D.
Perelman School of Medicine at the University of Pennsylvania 
Philadelphia, PA 
pjs@ mail . med . upenn . edu
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. Liverman CT, Blazer DB. Testosterone and aging: clinical 
research directions. Washington, DC: National Academies 
Press, 2003.
DOI: 10.1056/NEJMc1603665
Aspirin before Coronary Artery Surgery
To the Editor: The title of the article by Myles et 
al. (Feb. 25 issue)1 (“Stopping vs. Continuing As-
pirin before Coronary Artery Surgery”) indicates 
uncertainty about discontinuing aspirin before 
coronary-artery bypass grafting (CABG). How-
ever, the trial, Aspirin and Tranexamic Acid for 
Coronary Artery Surgery (ATACAS), does not ad-
dress that uncertainty. All patients discontinued 
aspirin at least 4 days before surgery, and risks of 
perioperative complications among patients who 
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